Abstract
Combination chemotherapy, where drugs with non-overlapping mode of actions achieve better efficacy at lower doses with reduced dose-dependent side effects, holds promise for complete remission of tumor. Herein, we report a combination therapeutic module comprised of folic acid receptor (FAR)-targeted SeNPs (FA-SeNPs) and MAPK pathway inhibitor PD98059 (PD98). While aberrant signaling leading to uncontrolled proliferation in BRAF-mutation bearing cancer cells including MDAMB231 (breast cancer) and A375 (melanoma) cells was inhibited by PD98, high expression of FAR by these cells also led to selective internalization of FA-SeNPs. Consequently, the combination treatment of PD98 and FA-SeNPs demonstrated synergistic anti-proliferative efficacy in MDAMB231 and A375 cells involving apoptotic mode of cell death. The selective nature of the present combination module was supported by low off-target response in L132 non-cancerous lung cells. Moreover, the size of three-dimensional MDAMB231 spheroids was successfully reduced because of the combination therapy projecting its potential in eradicating tumor in vivo.
Funding Information
  • Department of Science and Technology, Ministry of Science and Technology (SB/FTP/ETA-0122/2014)
  • Department of Biotechnology , Ministry of Science and Technology (BT/PR13560/COE/34/44/2015, DBT-NER/Health/47/2015)
  • Department of Electronics and Information Technology, Ministry of Communications and Information Technology (5(9)/2012-NANO (Vol. II))

This publication has 51 references indexed in Scilit: